What is the role of bosentan in healing of femur fractures in a rat model?
- 478 Downloads
The purpose of this study was to examine the effects bosentan (which is a strong vasoconstrictor) on bone fracture pathophysiology, and investigate the roles of the nonselective endothelin 1 receptor blocker bosentan on the bone fractures formed in rats through radiographic, histopathologic, and immunohistochemical methods. The rats were divided into three groups (six rats in each group): a femoral fracture control group, a femoral fracture plus bosentan at 50 mg/kg group, and a femoral fracture plus bosentan at 100 mg/kg group. The femoral fracture model was established by transversely cutting the femur at the midsection. After manual reduction, the fractured femur was fixed with intramedullary Kirschner wires. The radiographic healing scores of the bosentan 100 and 50 mg/kg groups were significantly better that those of the fracture control group. The fracture callus percent of new bone in the bosentan 100 mg/kg group was significantly greater than that in the control group. Also, semiquantitative analysis showed higher positive vascular endothelial growth factor and osteocalcin staining and lower positive endothelin receptor type A staining in the treatment groups than in the control group. Bosentan treatment also decreased tissue endothelin 1 expression relative to that in the fracture control group. As a result of our study, the protective effect of bosentan was shown in experimental femoral fracture healing in rats by radiographic, histopathologic, and molecular analyses.
KeywordsBosentan Endothelin 1 Bone fracture Rat Femur
We thank Marc Iglarz and Actelion Pharmaceuticals Ltd for providing us with bosentan. This work was supported by the Ataturk University Medical Research Council (grant number 2012/03).
Conflict of interest
None of the authors has a commercial interest, financial interest, and/or other relationship with the manufacturers of pharmaceuticals, laboratory supplies, and/or medical devices, or with commercial providers of medically related services.
- 43.Skjødt H, Russell G (1992) Bone cell biology and the regulation of bone turnover. In: Gowen M (ed) Cytokines and Bone Metabolism. CRC, Boca RatonGoogle Scholar
- 50.Yayla M, Halici Z, Unal B, Bayir Y, Akpinar E, Gocer F (2014) Protective effect of Et-1 receptor antagonist bosentan on paracetamol induced acute liver toxicity in rats. Eur J Pharmacol 726:87–95Google Scholar
- 60.Kayal RA, Tsatsas D, Bauer MA, Allen B, Al-Sebaei MO, Kakar S et al (2007) Diminished bone formation during diabetic fracture healing is related to the premature resorption of cartilage associated with increased osteoclast activity. J Bone Miner Res 22:560–568PubMedCentralCrossRefPubMedGoogle Scholar
- 61.James ND, Caty A, Borre M, Zonnenberg BA, Beuzeboc P, Morris T et al (2009) Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial. Eur Urol 55:1112–1123CrossRefPubMedGoogle Scholar
- 62.James ND, Caty A, Payne H, Borre M, Zonnenberg BA, Beuzeboc P et al (2010) Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-blind, placebo-controlled, randomized phase II trial. BJU Int 106:966–973CrossRefPubMedGoogle Scholar